Menu Search
Equities

Beam Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BEAM*:MEX

Beam Therapeutics Inc

Actions
  • Price (MXN)604.00
  • Today's Change137.97 / 29.61%
  • Shares traded50.00
  • 1 Year change--
  • Beta2.1426
Data delayed at least 20 minutes, as of Jan 13 2026 18:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

  • Revenue in USD (TTM)55.70m
  • Net income in USD-414.64m
  • Incorporated2017
  • Employees483.00
  • Location
    Beam Therapeutics Inc238 Main StreetCAMBRIDGE 02142United StatesUSA
  • Phone+1 (857) 327-8775
  • Fax+1 (302) 655-5049
  • Websitehttps://beamtx.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.